Kyntra Bio (KYNB) Current Deferred Revenue (2014 - 2026)
Kyntra Bio (KYNB) posted Current Deferred Revenue of $5.7 million for Q1 2026, up 6.89% sequentially from $5.3 million in Q4 2025, and down 74.77% YoY from $22.5 million in Q1 2025.
Kyntra Bio (KYNB) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Current Deferred Revenue for 13 years, with the latest figure at $5.7 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 74.77% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 74.77% YoY) and the FY2025 annual result came in at $5.3 million, down 80.53% from the prior year.
- Current Deferred Revenue rose to $5.7 million in Q1 2026 per KYNB's latest filing, from $5.3 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $28.9 million in Q3 2024 and troughed at $4.7 million in Q1 2022.
- A 5-year average of $13.9 million and a median of $12.7 million in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue surged 293.97% in 2024, then sank 82.31% in 2025.
- Over 5 years, Current Deferred Revenue stood at $12.7 million in 2022, then increased by 0.01% to $12.7 million in 2023, then jumped by 114.21% to $27.3 million in 2024, then plunged by 80.53% to $5.3 million in 2025, then gained by 6.89% to $5.7 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $5.7 million, $5.3 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.42 Mn |
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 5.31 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | 27.31 Mn |
| Mar 31, 2025 | 22.51 Mn |
| Dec 31, 2024 | 27.29 Mn |
| Sep 30, 2024 | 28.86 Mn |
| Jun 30, 2024 | 9.55 Mn |
| Mar 31, 2024 | 12.86 Mn |
| Dec 31, 2023 | 12.74 Mn |
| Sep 30, 2023 | 7.33 Mn |
| Jun 30, 2023 | 7.49 Mn |
| Mar 31, 2023 | 16.50 Mn |
| Dec 31, 2022 | 12.74 Mn |
| Sep 30, 2022 | 7.36 Mn |
| Jun 30, 2022 | 23.20 Mn |
| Mar 31, 2022 | 4.74 Mn |
| Dec 31, 2021 | 11.80 Mn |
| Sep 30, 2021 | 23.26 Mn |